NCT01664975 · ADVERSE EVENTS

Adverse events

Treatment of Peripheral T-cell Lymphoma · Source last updated 2016-10-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame: Not reported
Other-event reporting threshold: 0%

Participants affected / participants at risk, as reported
Safety group	Serious events	Other events	Deaths
GDPT Regimen GDPT(gemcitabine,cisplatin,Prednisone,Thalidomide) regimen GDPT regimen: GDPT regimen(Gemcitabine,Cisplatin,Prednisone ,Thalidomide) Cisplatin(DDP) 25 mg/m2,ivgtt（intravenously guttae）,d1-3;Prednisone 60mg/m2,p.o,d1-5;Gemcitabine(GEM) 800mg/m2,ivgtt,30min,d1,8;Thalidomide,p.o,200mg/d,Continued use to the end of chemotherapy .Every 21 days for one cycle and three cycles are required. Efficacy was evaluated every two cycles.	23 / 52	21 / 52	Not reported / Not reported
CHOP Regimen CHOP(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) regimen CHOP regimen: CHOP regimen(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Doxorubicin,50mg/m2,ivgtt,d1;Prednisone 60mg/m2,p.o, d1-5.	21 / 51	19 / 51	Not reported / Not reported

Group identifiers: EG000: GDPT Regimen · EG001: CHOP Regimen

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

organ System
Blood and lymphatic system disorders
stats
group Id
EG000
num Affected
23
num At Risk
52
group Id
EG001
num Affected
21
num At Risk
51
term
Grade3/4 myelosuppression

Other reported adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

organ System
Gastrointestinal disorders
stats
group Id
EG000
num Affected
21
num At Risk
52
group Id
EG001
num Affected
19
num At Risk
51
term
digestive tract toxicity

Complete source fields

event Groups

description
GDPT(gemcitabine,cisplatin,Prednisone,Thalidomide) regimen GDPT regimen: GDPT regimen(Gemcitabine,Cisplatin,Prednisone ,Thalidomide) Cisplatin(DDP) 25 mg/m2,ivgtt（intravenously guttae）,d1-3;Prednisone 60mg/m2,p.o,d1-5;Gemcitabine(GEM) 800mg/m2,ivgtt,30min,d1,8;Thalidomide,p.o,200mg/d,Continued use to the end of chemotherapy .Every 21 days for one cycle and three cycles are required. Efficacy was evaluated every two cycles.
id
EG000
other Num Affected
21
other Num At Risk
52
serious Num Affected
23
serious Num At Risk
52
title
GDPT Regimen
description
CHOP(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) regimen CHOP regimen: CHOP regimen(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Doxorubicin,50mg/m2,ivgtt,d1;Prednisone 60mg/m2,p.o, d1-5.
id
EG001
other Num Affected
19
other Num At Risk
51
serious Num Affected
21
serious Num At Risk
51
title
CHOP Regimen

frequency Threshold

other Events

organ System
Gastrointestinal disorders
stats
group Id
EG000
num Affected
21
num At Risk
52
group Id
EG001
num Affected
19
num At Risk
51
term
digestive tract toxicity

serious Events

organ System
Blood and lymphatic system disorders
stats
group Id
EG000
num Affected
23
num At Risk
52
group Id
EG001
num Affected
21
num At Risk
51
term
Grade3/4 myelosuppression

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice